Treatment patterns and disease burden of juvenile myasthenia gravis in the United States: a cohort study using healthcare claims databases (RWE0816)

Switching to SC zilucoplan from IV complement component 5 inhibitors in gMG: A Phase 3b, open-label study

Brivaracetam effectiveness and patient-reported outcomes in clinical practice: data from a 12-month prospective, observational study in the United States

Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period

Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study

Certolizumab pegol for plaque psoriasis in women of childbearing potential, pregnant or breastfeeding in clinical settings: One-year outcomes from the international noninterventional CIMREAL study

Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies

Incidence and Prevalence of Juvenile Myasthenia Gravis in the United States Between 2010 and 2020: Analysis of Two Claims Databases

Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis

High‑Dose Steroids, Treatment Escalation, and Healthcare Burden in Myasthenia Gravis: A US Claims‑Based Cohort Study